Lonza Pharma and Biotech and Denali Therapeutics asserted having entered into a strategic partnership on Denali’s biologic pipeline products for neurodegenerative diseases.The agreement covers all aspects of development and manufacturing.
Denali will have access to Lonza’s extensive expertise and technologies: from cell-line development using the GS Xceed Gene Expression System to process development and manufacturing at facilities in Slough (UK) and Hayward, CA (USA). In addition, Lonza’s in-house Drug Product Services in Basel (CH) will focus on ensuring that Denali’s finished product candidates are designed with optimal formulation, stability and delivery system in mind.
Lonza Pharma & Biotech’s COO, Marc Funk, commented, “We’re taking up the challenge with Denali and helping them bring potential therapies to patients suffering from these debilitating diseases. This partnership will allow us to do what we do best for our customers – leverage our expertise across the development cycle and anticipate Denali’s needs as they move from pre-clinical to clinical and beyond.”
Neurodegenerative diseases represent one of the great unmet medical needs and scientific challenges of today. The prevalence of Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases is increasing and represents a significant medical and financial burden on patients, families and society at large.